Sanguinarine feed additive in lambs: 28 days, two doses
A sanguinarine feed additive built from Macleaya cordata lifted average daily gain in lambs from 75.71 to 155.71 grams per day over 28 days. Serum IgG, IL-6 and IFN-gamma all came up. IL-4 and IL-10 went down. Blautia abundance dropped hard. The arachidonic acid pathway came out reworked. Which immune signature you get depends on the dose.
What a sanguinarine feed additive does in a lamb, in one paragraph
Sanguinarine (SNG) belongs to the benzophenanthridine alkaloids. The commercial form is a Macleaya cordata extract, and growers have used the plant for years as a source of antimicrobial alkaloids. Pigs and broilers already have a decade of published work on a sanguinarine feed additive, covering growth, pathogen load in the gut and cytokine expression. That is why a dietary alkaloid feed additive is taken seriously as a category. Ruminants were the hole in the story. This trial fills part of it, and it is the most careful look so far at sanguinarine in lamb diets. The answer is not a flat yes.
Four groups of lambs, one basal diet. Two groups got graded doses of the same extract. One group got the diclazuril positive control. Gut microbiota and immunity in lambs were measured from both ends. On the host side, growth performance and serum immune and antioxidant markers. On the microbial side, 16S rRNA sequencing of gut microbiota and untargeted fecal metabolomics.
The numbers arrange themselves into one mechanism. Sanguinarine suppressed Blautia. Losing Blautia freed arachidonic acid metabolism. The lipid mediators that came out reset the cytokine profile toward Th1. That is a Th1 immune response in ruminants, driven from the microbiome rather than from an immune cell target.
Growth is the headline. That chain is the part a nutritionist can actually work with.
Why inflammation decides how fast a lamb grows
On a ruminant operation, immune status is not a welfare line item. It sits on the growth curve.
Intensive systems stack stressors on the animal at the same time: nutritional, environmental, microbial. Those stressors break immune and metabolic homeostasis, and the break shows up as inflammation-associated growth suppression. Intake looks fine. The animal looks fine. The weight does not come, and feed conversion quietly slides.
Phytogenic feed additives get used here because they seem to release that pressure through the gut instead of through a drug target. They reshape the microbiome and its metabolic output. The reshaped metabolome then talks to the host immune system.
The arachidonic acid pathway is the hinge. Arachidonic acid metabolism sits between lipid metabolism and immune function, and it makes the eicosanoids that run both ends of an inflammatory event. Eicosanoids and inflammation resolution sit on the two sides of that pathway. Prostaglandins and leukotrienes start it. Lipoxins finish it. Move the microbial community and you move the substrate flow through the pathway. Move the flow and different cytokines come out the far side.
That was the hypothesis. The data back it.
Trial design: two sanguinarine doses against a coccidiostat
Twenty-four Hu lambs, 60 days old, four groups of six. Feed went out twice a day at 08:00 and 18:00, water always available. The extract ran 2 percent pure sanguinarine by weight and was blended into the basal diet. Every two weeks the inclusion rate was recalculated against live weight, so the pure sanguinarine intake per kilogram of body weight held steady.
| Group | Diet | Pure sanguinarine intake | Role in the design |
| CON | Basal diet only | none | Untreated baseline |
| SL | Basal diet plus 200 mg/kg body weight SNG extract | 4 mg/kg body weight | Low dose |
| SH | Basal diet plus 800 mg/kg body weight SNG extract | 16 mg/kg body weight | High dose |
| DIC | Basal diet plus diclazuril at 2 mg/kg body weight | none | Drug comparison |
| Parameter | Detail |
| Animals | 24 Hu lambs, 60 days old, six per group |
| Trial length | 28 days |
| Housing | Individually housed, uniform environment and management |
| Feeding | Twice daily at 08:00 and 18:00, water ad libitum |
| Dose adjustment | Recalculated every two weeks against live weight |
| Growth measurement | Body weight on day 1 and day 28, all 24 lambs |
| Omics and serum subset | 4 lambs randomly selected from each group, giving 16 serum and 16 fecal samples |
| Microbiota method | 16S rRNA gene sequencing of the V3 to V4 region, primers 338F and 806R, Illumina MiSeq |
| Metabolomics method | Untargeted UPLC-MS on 100 mg fecal material extracted in pre-cooled 80 percent methanol |
| Statistics | PERMANOVA for community differences, LSD tests for multiple comparisons, significance at p below 0.05 |
The basal diet the lambs actually ate
Every group ate the same total mixed ration, formulated for growing lambs. Dry matter was measured in the lab. The rest of the nutrient figures were calculated from a national feed composition database.
| Component or nutrient | Value |
| Peanut vine | 37.50 percent of the diet |
| Corn | 28.10 percent |
| Soybean meal | 21.90 percent |
| Wheat bran | 6.25 percent |
| Sodium bicarbonate | 2.50 percent |
| Premix (4 percent growing lamb premix) | 1.25 percent |
| Salt | 1.25 percent |
| Calcium hydrogen phosphate | 1.25 percent |
| Dry matter | 89.2 percent |
| Crude fiber | 17.6 percent |
| Crude protein | 14.3 percent |
| Crude fat | 2.3 percent |
| Crude ash | 6.1 percent |
| Calcium | 1.07 percent |
| Phosphorus | 0.38 percent |
The premix carried the usual vitamin and trace element load for a growing lamb: vitamins A, D3, E and K, niacin, biotin, iron, copper, manganese, zinc, iodine, selenium, cobalt. Nothing exotic anywhere in the ration. This is a working forage diet on a peanut vine and corn base, and that matters the moment you try the result on a different system.
Hu lamb growth performance: the feed additive separates from the drug
Average daily gain in lambs was the primary growth endpoint, and the trial chose it for a reason. The groups did not start level. Initial body weight differed significantly among them despite random allocation, and that carried straight into final body weight. Average daily gain strips the baseline problem out.
| Item | CON | DIC | SL (200 mg/kg) | SH (800 mg/kg) |
| Initial body weight (kg) | 24.98 | 34.16 | 30.24 | 25.72 |
| Final body weight (kg) | 26.94 | 36.28 | 33.84 | 30.08 |
| Average daily gain (g/day) | 75.71 | 75.71 | 128.57 | 155.71 |
Sanguinarine supplementation moved average daily gain significantly. The high dose hit 155.71 grams per day, clearly above the untreated control and above diclazuril, at p = 0.034 on both pairwise comparisons. The low dose hit 128.57 grams per day. That is a big gap in absolute terms, but it landed at p = 0.146 against the control, which is a trend and not a result. The low and high doses did not separate from each other at p = 0.444.
Now the diclazuril group. Its average daily gain was 75.71 grams per day. Identical to the untreated control. Pairwise p value of 1.000. A coccidiostat run as a positive control delivered no growth response at all. Whatever the drug route was doing down there, it was not moving the animal.
| Pairwise comparison on average daily gain | p value |
| CON vs SL | 0.146 |
| CON vs SH | 0.034 |
| CON vs DIC | 1.000 |
| SL vs SH | 0.444 |
| SL vs DIC | 0.146 |
| SH vs DIC | 0.034 |
So the growth benefit lives at the high dose at 28 days, and the spread between the two doses is wide enough that the low dose is a trend. Nobody can claim a linear dose response from this. The design never tested for one, and the authors say so.
Serum immune and antioxidant response: a Th1 shift with lower antioxidant enzymes
Here is where the mechanism turns visible. IgG climbed. The Th1 cytokines IL-6 and IFN-gamma climbed. The Th2 cytokines IL-4 and IL-10 dropped. IL-1 beta sat completely still. Every antioxidant enzyme fell. Malondialdehyde did not move.
| Parameter | CON | DIC | SL | SH | p value |
| T-AOC (U/mL) | 27.17 | 26.80 | 17.75 | 17.72 | below 0.001 |
| SOD (U/mL) | 114.24 | 123.90 | 75.04 | 76.67 | below 0.001 |
| GSH-Px (U/mL) | 428.57 | 379.96 | 274.32 | 292.03 | below 0.001 |
| MDA (nmol/mL) | 4.66 | 5.78 | 4.79 | 5.25 | 0.0095 |
| IgG (mg/mL) | 14.88 | 14.25 | 22.25 | 21.58 | below 0.001 |
| IL-4 (pg/mL) | 152.60 | 133.13 | 80.25 | 73.83 | below 0.001 |
| IL-6 (pg/mL) | 86.71 | 108.97 | 155.37 | 158.60 | below 0.001 |
| IL-10 (pg/mL) | 54.56 | 47.21 | 48.55 | 45.80 | 0.023 |
| IL-1 beta (pg/mL) | 84.01 | 83.06 | 88.97 | 91.31 | 0.57 |
| IFN-gamma (pg/mL) | 677.90 | 583.87 | 866.50 | 815.19 | below 0.001 |
Start with the immunoglobulin row, because it leaves the least room for argument. Serum immunoglobulin G in lambs went from about 15 mg/mL in both controls to about 22 mg/mL in both treated groups. Both doses landed in the same place. The immunoglobulin arm looks like it saturates early.
Then read the cytokines as a pair. IFN-gamma rose by roughly 190 pg/mL at the low dose and 137 pg/mL at the high dose over the untreated control. IL-4 dropped from 152.60 to 80.25 and 73.83 pg/mL. IL-10 fell modestly but significantly at the high dose. IL-1 beta, the textbook acute inflammatory signal, did not budge.
That is a Th1 shift. It is not a general inflammatory flare, and the flat IL-1 beta is what separates the two.
One more thing worth flagging for anyone comparing this against the drug route. Diclazuril showed no significant difference from the untreated control for most serum parameters. The serum changes tracked the feed additive, and only the feed additive.
Gut microbiota: Blautia falls, Monoglobus and Colidextribacter rise
Sequencing covered the V3 to V4 region of the bacterial 16S rRNA gene across 16 fecal samples. Alpha diversity indices, Chao1, ACE, Shannon and Simpson, ran higher in every treated group than in the untreated control, and significantly higher in the low dose and diclazuril groups.
Bray-Curtis beta diversity tells a narrower and more honest story. Community structure did not differ significantly among groups, at PERMANOVA p = 0.084 with an R-squared of 0.259. The overall shape of the community held. What changed was the abundance of specific members inside it. That is a much smaller claim than “sanguinarine remodels the microbiome”, and it is the claim the data carry.
| Taxon | Direction | Where it changed | Significance |
| Firmicutes | Dominant throughout | All groups | Baseline phylum |
| Bacteroidota | Decreased | Diclazuril and high dose | p below 0.05 |
| Campylobacterota | Enriched | High dose only | p below 0.05 |
| Desulfobacterota | Enriched | High dose only | p below 0.05 |
| Patescibacteria | Increased | Low dose only | p below 0.05 |
| Monoglobus | Increased | All treated groups, strongest at high dose | p below 0.05 |
| Colidextribacter | Increased | All treated groups, strongest at high dose | p below 0.05 |
| Blautia | Decreased | Low and high dose | p below 0.001 |
| Roseburia | Decreasing trend | All treated groups | trend |
LEfSe at an LDA score threshold of 2.0 turned up 21 differentially abundant genera across the four groups. Blautia and Roseburia were enriched in the untreated control. Marvinbryantia and Acetitomaculum marked the low dose. Victivallis and Lysinibacillus marked the high dose. Pseudobacteroides and Succinimonas marked the diclazuril group.
The top two genera by LDA score from each group went forward. Four of those eight had higher relative abundance and consistent responses, so they went into a random forest and an ROC analysis. Blautia won outright, with a Gini importance of 3.174 and a classification AUC of 0.979. It is the most responsive and most discriminative single genus in the set.
| Biomarker metric | Result |
| Genera identified by LEfSe | 21 |
| Most important genus | Blautia |
| Gini feature importance | 3.174 |
| Classification AUC | 0.979 |
| Enriched in untreated control | Blautia, Roseburia |
| Enriched in low dose | Marvinbryantia, Acetitomaculum |
| Enriched in high dose | Victivallis, Lysinibacillus |
| Enriched in diclazuril group | Pseudobacteroides, Succinimonas |
PICRUSt2 functional prediction filled in what those shifts might do. The low dose group showed more fructose and mannose metabolism and less aromatic and branched-chain amino acid biosynthesis. The high dose group showed enriched sphingolipid metabolism and phosphatidylinositol signaling, with D-alanine metabolism and protein export reduced.
Keep the high dose result. Sphingolipid metabolites such as ceramide are long established mediators of inflammation and apoptosis. A functional prediction pointing at lipid signaling in the group that also showed the strongest immune shift is coherent evidence. It is still inference from gene content rather than a measurement, so treat it as such.
Two genera earn a note. Monoglobus is a pectin-degrading specialist, so its rise suggests the animal is getting more out of the fiber in that peanut vine and wheat bran ration. Colidextribacter ties to polysaccharide metabolism and to short-chain fatty acids, particularly propionate. Both changes point toward more energy substrate reaching the animal. That is a small instance of immuno-metabolic coupling, and a plausible contributor to the growth response.
Fecal metabolomics: arachidonic acid metabolism takes over
Fecal metabolomics ran on UPLC-MS in untargeted mode. Principal component analysis separated the groups cleanly and stably across total ion, positive ion and negative ion modes, so the metabolic difference between treatments was real and not an artefact of one acquisition mode. Pairwise OPLS-DA models confirmed clear discrimination between both supplemented groups and the untreated control.
With thresholds set at absolute fold change above 1, VIP above 1 and p below 0.05, the run produced 424 differential metabolites across the comparisons.
| Comparison | Upregulated | Downregulated | Total differential metabolites |
| Low dose vs control | 138 | 21 | 159 |
| High dose vs control | 173 | 92 | 265 |
The top 30 differential metabolites for both comparisons were dominated by lipid compounds: prostaglandin E2, leukotriene B4, linoleic acid derivatives. Those sit inside arachidonic acid metabolism, and they were more abundant in the supplemented groups than in the control. Quantification confirmed significantly elevated levels of arachidonic acid derived compounds in both supplemented groups.
The two doses ran in different directions, and this is the most useful thing in the dataset. At the high dose, 20-hydroxy leukotriene B4 accumulated. That compound is a close relative of leukotriene B4, a potent chemotactic and immune-activating lipid mediator, so its rise fits immune cell recruitment. At the same time 15(S)-HpEPE, a precursor of pro-resolving lipoxins, also trended up. The high dose raised the activating side and the resolving side together.
The low dose went the other way. It shifted toward 15(R)-lipoxin A4 and 15-epiprostaglandin E1, both classic inflammation-resolving lipid mediators. Both inhibit neutrophil infiltration and promote macrophage clearance of apoptotic cells. That is a recovery-forward signature, not an activation-forward one.
| Sanguinarine dose | Dominant lipid mediator shift | What that signature suggests |
| 4 mg/kg body weight | 15(R)-lipoxin A4, 15-epiprostaglandin E1, 1a,1b-dihomo prostaglandin F2 alpha | Inflammation resolution and tissue recovery |
| 16 mg/kg body weight | 20-hydroxy leukotriene B4, 15(S)-HpEPE | Immune activation paired with a resolution program |
KEGG pathway enrichment then placed those metabolites in pathways. In the low dose comparison, ovarian steroidogenesis at p = 0.021 and the citrate cycle at p = 0.022 came up enriched, with AMPK signaling, propanoate metabolism and steroid hormone biosynthesis trending at p = 0.08. In the high dose comparison, differential metabolites mapped mainly to arachidonic acid metabolism at p = 0.065, tryptophan metabolism at p = 0.065 and fatty acid metabolism at p = 0.122.
| Comparison | Pathway | p value |
| Low dose vs control | Ovarian steroidogenesis | 0.021 |
| Low dose vs control | Citrate cycle (TCA cycle) | 0.022 |
| Low dose vs control | AMPK signaling, propanoate metabolism, steroid hormone biosynthesis | 0.08 trend |
| High dose vs control | Arachidonic acid metabolism | 0.065 |
| High dose vs control | Tryptophan metabolism | 0.065 |
| High dose vs control | Fatty acid metabolism | 0.122 |
Several of those sit above the conventional significance line, and the authors reported them as trends rather than confirmed effects. So keep the statement narrow. The same pathway, arachidonic acid metabolism, showed a repeated enrichment trend in both supplemented groups, and its eicosanoid products moved in the same direction at the metabolite level. Pathway level p values and metabolite level changes agreeing is meaningful. Neither one alone would be.
The counterintuitive finding: antioxidant enzymes fell and nothing oxidised
Lower antioxidant enzymes after a feed additive reads like a problem. In most contexts it gets treated as one. Total antioxidant capacity, reported as T-AOC, fell from 27.17 to 17.75 U/mL. SOD fell from 114.24 to about 76 U/mL. GSH-Px fell from 428.57 to roughly 280 U/mL. Every one of those drops was significant at p below 0.001.
Now the malondialdehyde line. No change. MDA is the standard readout for lipid peroxidation, and a large fall in antioxidant buffering with a flat MDA is not what oxidative damage looks like.
What it looks like is a reallocation of antioxidant enzymes in lambs toward immune work. Early in an immune response, controlled reactive oxygen species generation acts as a signal in its own right. It supports phagocytic bactericidal activity and cytokine signal transduction. A moderate reduction in antioxidant buffering can enhance ROS-dependent signaling, including the hydrogen peroxide mediated activation of nuclear factor kappa B. That lowers the activation threshold of macrophages and pushes them toward the Th1 phenotype. Reactive oxygen species in that setting also support M1 macrophage polarization and the IFN-gamma and IL-6 output that comes with it.
Read that way, the antioxidant enzymes were not failing. They were being spent on immune activation instead of being held in reserve. The authors call it controlled oxidative activation, and they are explicit that reactive oxygen species were never measured directly here. Treat the mechanism as a hypothesis with supporting indirect evidence, not as a demonstrated pathway.
One calibration case helps. In dairy cows exposed to deoxynivalenol, low antioxidant enzyme activity sits alongside a genuine oxidative insult. What separates the two situations is everything else that moves at the same time. Here MDA held, IgG and IFN-gamma rose, and growth improved. Those three together are hard to reconcile with a damaged animal.
Mediation analysis: from Blautia to lipid mediator to cytokine
Correlation and mediation analysis tied the microbial change to the immune change through the lipid mediators. This is the section that welds three separate result sets into one mechanism.
| Group | Microbial variable | Lipid mediator | Immune target | Mediation result |
| High dose | Blautia abundance, negatively correlated | 15(S)-HpEPE | IFN-gamma and IgG | Full mediation |
| High dose | Blautia abundance, negatively correlated | 20-hydroxy leukotriene B4 | IFN-gamma and IL-4 | Complete mediation |
| High dose | Blautia abundance, negatively correlated | 20-hydroxy leukotriene B4 | IFN-gamma and IL-6 | Partial mediation |
| Low dose | Blautia abundance, negatively correlated with 15-epiprostaglandin E1 and 1a,1b-dihomo prostaglandin F2 alpha | Both mediators named | IL-6 | Full mediation |
| High dose | Blautia abundance, positively correlated with PG(4:0-16:0) | PG(4:0-16:0) | Not specified as a mediator | Correlation only |
In the high dose group, Blautia abundance correlated negatively with 15(S)-HpEPE and with 20-hydroxy leukotriene B4, both at p below 0.05, and positively with PG(4:0-16:0). Mediation analysis showed 15(S)-HpEPE fully mediated the effect of Blautia on IFN-gamma and IgG. 20-hydroxy leukotriene B4 acted as a complete mediator for IFN-gamma and IL-4 and a partial mediator for IFN-gamma and IL-6.
In the low dose group, Blautia abundance correlated negatively with 15-epiprostaglandin E1 and 1a,1b-dihomo prostaglandin F2 alpha. Those two metabolites completely mediated the effect of Blautia on IL-6.
Both doses ran through the same pivot, Blautia abundance, and out through the same pathway, arachidonic acid metabolism. Only the dominant branch differed.
The Blautia mechanism is plausible on existing literature. Blautia is a butyrate producer, and butyrate plus secondary bile acid metabolites can suppress Th1 and Th17 type responses by inhibiting dendritic cell activation. Cut Blautia abundance and that suppression lifts, which makes a Th1 dominant phenotype easier to reach. Immune activation also shifts the metabolic and redox environment of the gut, which can make life harder for strict anaerobes like Blautia and reinforce the fall.
Whether the primary driver is the lost immunosuppressive signal or the changed gut environment cannot be settled from this dataset. Both fit the correlations.
Feed additive and coccidiostat: two banks of the same inflammatory river
Put the two treatment routes side by side and the shape of the result snaps into focus. They touch overlapping biology. They do not produce the same animal.
| Dimension | Feed additive route: sanguinarine | Drug route: diclazuril |
| Level of action | Upstream, on the gut microbial community | Downstream, on the parasite itself |
| Microbial signature | Blautia down, Monoglobus and Colidextribacter up | Bacteroidota down, Pseudobacteroides and Succinimonas enriched |
| Alpha diversity | Raised | Raised |
| Community structure | No significant shift, PERMANOVA p = 0.084 | No significant shift |
| Growth | 155.71 g/day at the high dose, significant against control | 75.71 g/day, identical to control, p = 1.000 |
| Serum immunity | IgG, IL-6 and IFN-gamma up, IL-4 and IL-10 down | No significant change for most parameters |
| Functional role in a program | Production and immune shaping | Disease control |
Two routes, one river. Both act on the gut. Both leave a microbial fingerprint. Both raise alpha diversity in the same way. Then they split completely on the endpoint that pays the feed bill. The coccidiostat did whatever it was aimed at and produced no growth response. The feed additive produced a large one, and the design carried no antiparasitic claim at all.
That is the practical argument. Feed-side inflammation regulation and drug-side inflammation suppression are related, and they are not interchangeable. They meet on the same arachidonic acid and cytokine machinery. They walk in from different banks. A drug that clears a pathogen downstream does not automatically restore the immune metabolic efficiency that a microbial shift upstream appears to restore, and this dataset shows the gap cleanly.
How to position a sanguinarine feed additive in a ruminant program
- Pick the objective before the dose. Steady immune support with resolution signaling points at the low dose. Maximum growth and a stronger Th1 shift point at the high dose.
- Do not read the low dose as equivalent. It reached 128.57 grams per day against 75.71 for the control, which is a wide numerical gap, and the pairwise p value was still 0.146. Underpowered evidence stays underpowered.
- Keep the diclazuril comparison in view when you price the additive. The drug delivered zero growth response here, so the two products are not bidding for the same slot in the ration.
- Check the fiber profile of your ration before you expect the microbial response to repeat. Monoglobus is a pectin degrader and Colidextribacter works on polysaccharides. A diet with less fermentable fiber may not support the same shift.
- Never build a program on the antioxidant number alone. Lower T-AOC, SOD and GSH-Px look alarming in isolation and mean something different when malondialdehyde is flat and IgG is climbing.
- Treat the immune shift as a trade, not a free gain. IFN-gamma and IL-6 rising is an activation signal. In a herd already fighting an inflammatory challenge that is a different proposition than in a healthy growing cohort, and this trial never tested a sick population.
- Plan the measurement before you plan the claim. Body weight on day 1 and day 28 with one serum collection at the end gives you a single time point. If you want to know how fast the response develops, you need intermediate sampling. This design does not offer it.
Because the immune and inflammatory cytokines in lambs respond to a whole ration and not to one ingredient, any trial you run should keep the rest of the diet fixed and change only the additive. Otherwise the effect you measure will not be the effect you bought.
Limitations to carry forward
The trial states its own limitations, and they bound what the numbers can carry.
Initial body weight differed significantly among groups despite random allocation. That can interfere with growth interpretation even with average daily gain used to compensate. The high dose group started lightest and finished with the highest gain, which is the most favorable version of that configuration and also the one that most needs repeating.
No formal dose-trend test was run, so a linear dose response cannot be confirmed. The gap between 4 and 16 mg/kg body weight is wide, and the ground between them is untested.
Reactive oxygen species were never measured directly, so controlled oxidative activation rests on indirect markers. It fits the data. It is not proven.
Several pathway enrichments sit above the conventional significance line and were reported as trends. Two groups of six lambs, with omics run on four per group, is a thin base for multi-omics integration, and mediation analysis on 16 samples is exploratory by nature.
Safety, residue and withdrawal data fall outside this work. The trial ran 28 days with no adverse finding, which is a useful signal and not a safety dossier.
Finally, the lambs received the extract against one specific forage-based diet on a peanut vine and corn base. Feed additive responses in ruminants are diet dependent. A different ration, breed or production stage needs its own verification.
Bottom line
Sanguinarine from Macleaya cordata improved average daily gain in lambs at 16 mg/kg body weight, raised serum IgG, IL-6 and IFN-gamma, cut IL-4 and IL-10, suppressed Blautia, and reshaped arachidonic acid metabolism toward eicosanoids that changed with the dose. The high dose raised activation and resolution at the same time. A coccidiostat run alongside produced no growth response, which is the cleanest evidence here that feed-side and drug-side inflammation management are not the same intervention.
The chain, from Blautia through an arachidonic acid mediator to a cytokine, is consistent, mechanistically plausible and built on a small sample. Strong hypothesis. Weak basis for a specification. Run your own dose gradient on your own diet before you write one.
FAQ
Does sanguinarine improve growth in lambs?
Yes, at the higher dose. Over 28 days, average daily gain in lambs on 16 mg/kg body weight of pure sanguinarine reached 155.71 grams per day, against 75.71 grams per day on the basal diet, and that difference was statistically significant. The low dose reached 128.57 grams per day, numerically higher than the control but well short of statistical separation.
What dose of sanguinarine should you feed a lamb?
The trial used an extract standardized to 2 percent pure sanguinarine, fed at 200 or 800 mg per kg body weight, equal to 4 or 16 mg of pure sanguinarine per kg body weight. It was blended into the basal diet and the rate was recalculated every two weeks against live weight. Only the high dose produced a significant growth response.
What is sanguinarine made from?
Sanguinarine is a benzophenanthridine alkaloid extracted from Macleaya cordata, a plant in the poppy family. The extract used in this kind of work is standardized to a fixed percentage of pure sanguinarine, most often 2 percent, and mixed into the total mixed ration rather than dosed as a pharmaceutical. The alkaloid has established antimicrobial and anti-inflammatory reports in pigs and broilers.
Can a plant alkaloid feed additive replace a coccidiostat?
Not on this evidence. Diclazuril had no effect on average daily gain, which stayed at 75.71 grams per day, identical to the untreated control. Sanguinarine nearly doubled it. The two routes moved the microbiome in overlapping ways, and only the feed additive changed growth. Treat them as different tools that touch the same biology, not as substitutes.
Why are antioxidant enzymes lower with sanguinarine?
Serum T-AOC, SOD and GSH-Px all fell sharply, yet malondialdehyde did not move. Malondialdehyde is the standard marker of lipid peroxidation, so a fall in enzyme activity without a rise in malondialdehyde points to antioxidant capacity being redirected into immune activation rather than to oxidative stress. The reported explanation is controlled oxidative activation.
How does Blautia abundance affect lamb immunity?
Blautia is a butyrate producer that suppresses Th1 and Th17 type responses in other systems. Sanguinarine cut Blautia abundance significantly in both treated groups, and mediation analysis showed that arachidonic acid derived lipid mediators carried most of the effect from Blautia through to IFN-gamma, IgG, IL-6 and IL-4. Losing that brake releases the Th1 arm.
Which lipid mediators change after sanguinarine?
Two lead. 20-hydroxy leukotriene B4, a leukotriene B4 relative and a chemotactic signal, accumulated at the high dose. 15(S)-HpEPE, a precursor of pro-resolving lipoxins, also tended to rise. At the low dose the shift ran toward 15(R)-lipoxin A4 and 15-epiprostaglandin E1, both classic inflammation-resolving mediators. One pathway, opposite emphases.
Does sanguinarine increase or decrease inflammation?
Both, depending on dose and on which arm you read. IFN-gamma and IL-6 rose, which is a Th1 activation signal, while IL-4 and IL-10 fell. IL-1 beta did not change at all. The interpretation offered is a controlled, self-limiting Th1 response rather than pathological inflammation, with resolving mediators rising alongside the activating ones.
How long does sanguinarine take to work in lambs?
The trial ran 28 days, with body weight recorded on day 1 and day 28, and blood and fecal samples collected at the end. Growth and immune endpoints were therefore read at a single 28 day time point. Nothing in the design shows how quickly the effect appears, or whether it holds past four weeks. Onset speed would need intermediate sampling that this trial did not include.
Is sanguinarine safe for lambs?
Within this trial no adverse effect appeared at either dose. Malondialdehyde, the lipid peroxidation marker, was unchanged, and no growth penalty accompanied the immune shift. That said, 24 lambs over 28 days is a small safety base, and no residue, tolerance or withdrawal data were reported. Commercial safety needs its own evidence.
Which gut bacteria does sanguinarine suppress?
Blautia and Roseburia both trended down, and Blautia fell significantly in both treated groups with a random forest importance score of 3.174 and a classification AUC of 0.979, making it the most sensitive single marker of treatment. Monoglobus and Colidextribacter rose instead, most strongly at the high dose.
Can you mix sanguinarine with other feed additives?
Nothing in this trial tested a combination. Sanguinarine was fed alone against a plain basal diet and a diclazuril control, so stack effects are unknown. A viability check is worth building, because alkaloids are antimicrobial and a broad effect on the microbiome could work against a probiotic or a live yeast in the same ration.
